(Linagliptin and metformin hydrochloride')

Linagliptin and metformin hydrochloride 
LINALIGLIP 2.5/500  are two medications commonly used in combination for the management of type 2 diabetes mellitus. They work through different mechanisms to help control blood sugar levels.
Linagliptin: Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by inhibiting the enzyme DPP-4, which is responsible for the breakdown of incretin hormones such as glucagon-like peptide-1 (GLP-1). By inhibiting DPP-4, linagliptin increases the levels of GLP-1, which stimulates insulin secretion and reduces the production of glucagon. This helps to regulate blood sugar levels and improve glycemic control.
Metformin hydrochloride: Metformin is a medication classified as a biguanide. It primarily works by reducing the production of glucose in the liver, decreasing intestinal glucose absorption, and improving insulin sensitivity in the muscles and tissues. Metformin helps to lower blood sugar levels by increasing the uptake and utilization of glucose by the body's cells.
The combination of LINALIGLIP 2.5/500  provides complementary actions in the management of type 2 diabetes. Linagliptin helps to increase the levels of GLP-1, which promotes insulin release and inhibits glucagon production. Metformin reduces the production of glucose in the liver, improves insulin sensitivity, and enhances glucose utilization by the body's cells.
By combining these medications, the goal is to achieve better glycemic control and improve overall management of blood sugar levels in individuals with type 2 diabetes. The combination is typically prescribed for individuals who have not achieved adequate blood sugar control with either medication alone.
For further information please contact: info@sterispharma.com Order Now -  https://www.sterisonline.com/product/linaliglip-2-5-500-134273